Cherry (C3RY) Q3 2024 TU earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2024 TU earnings summary
19 Jan, 2026Executive summary
Q3 2024 results were significantly below expectations, with a revenue shortfall of EUR 13 million and negative adjusted EBITDA margin, leading to a EUR 6 million cash burn in the quarter.
Weakness was most pronounced in the Gaming and Office Peripherals segment, driven by poor German market conditions, internal management issues, and order delays in Components.
Management is implementing restructuring, leadership changes, sales team reorganization, and a hiring freeze to address challenges.
Financial highlights
Group sales for the first nine months of 2024 were EUR 84 million, with Q3 sales at EUR 22.6 million, down 17% year-over-year.
Adjusted EBITDA for Q3 was -EUR 3.1 million, with a nine-month adjusted EBITDA of -EUR 0.7 million and margin of -0.8%.
Gaming & Office Peripherals posted a negative Q3 earnings contribution of EUR -1.5 million.
Digital Health & Solutions segment generated over EUR 2 million in Q3 earnings, improving from a loss in Q3 2023.
Cash burn in Q3 totaled EUR 6 million.
Outlook and guidance
Full-year 2024 group revenue now expected at EUR 120 million, with adjusted EBITDA margin around 3%, revised down from previous guidance.
Q4 2024 implied sales of EUR 35.9 million and adjusted EBITDA margin of 11%, assuming full cost savings.
Management expects restructuring benefits to materialize in 2025, with a focus on internationalization and margin stabilization.
Latest events from Cherry
- 2025 revenue fell 15% to €94.3M, with cost cuts, margin recovery, and segment review ongoing.C3RY
Q4 20255 Mar 2026 - 2024 guidance targets €140m–€150m revenue and a 7–8% EBITDA margin, signaling a strong turnaround.C3RY
Investor presentation4 Feb 2026 - Revenue and EBITDA fell short, triggering cost cuts and a revised €120m 2024 outlook.C3RY
Investor presentation4 Feb 2026 - Streamlined for margin-driven growth, with €120M 2024 revenue forecast and €3.5M cost savings.C3RY
Investor presentation4 Feb 2026 - Restructuring, M&A, and operational streamlining target a return to growth and financial stability.C3RY
Investor presentation4 Feb 2026 - Digital Health & Solutions growth and cost controls support outlook despite margin pressure.C3RY
Q2 20243 Feb 2026 - Revenue and margins fell, but Q4 free cash flow rose as restructuring targets 2025 recovery.C3RY
Q4 2024 TU26 Dec 2025 - Restructuring and SaaS focus aim to restore profitability and drive growth in 2025.C3RY
Analyst Day 202525 Nov 2025 - 9M 2025 revenue down 16%, Q3 up 9.3% YoY; net loss widens amid restructuring.C3RY
Q3 2025 TU17 Nov 2025